Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~* Must have 1 of the following 9 CFTR mutations on at least 1 allele: G551D, G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P, or G1349D~* On ivacaftor therapy~* FEV1 value ≥40% and ≤100% of predicted mean for age, sex, and height~Key Exclusion Criteria:~* History of clinically significant cirrhosis with or without portal hypertension~* History of solid organ or hematological transplantation~* Lung infection with organisms associated with a more rapid decline in pulmonary status~Other protocol defined Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ivacaftor (Type: ACTIVE_COMPARATOR): Participants received IVA 150 milligrams (mg) orally every 12 hours (q12h) in the treatment period for 12 weeks.
- VX-561: 25 mg (Type: EXPERIMENTAL): Participants received VX-561 25 mg orally daily (qd) in the treatment period for 12 weeks.
- VX-561: 50 mg (Type: EXPERIMENTAL): Participants received VX-561 50 mg orally qd in the treatment period for 12 weeks.
- VX-561: 150 mg (Type: EXPERIMENTAL): Participants received VX-561 150 mg orally qd in the treatment period for 12 weeks.
- VX-561: 250 mg (Type: EXPERIMENTAL): Participants received VX-561 250 mg orally qd in the treatment period for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).